02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
03:11 , Jan 13, 2018 |  BioCentury  |  Finance

JPM jolt

Fifteen biotechs that presented at the 2018 J.P. Morgan Healthcare Conference posted gains of at least 15%, with Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) leading the risers after announcing that its board rejected two unsolicited acquisition proposals...
21:39 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

QIMR reports updated Phase I data for MS candidate

Atara Biotherapeutics Inc. (NASDAQ:ATRA) said QIMR Berghofer Medical Research Institute (Brisbane, Australia) reported updated data from a Phase I trial in 10 patients with primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS) showing...
19:59 , Apr 11, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models LMP1 / LMP2 -overexpressing mice depleted of T cells and NKT cells could be used to screen therapies for EBV-positive lymphoproliferative disease. Mice with germinal center B cell-specific overexpression of LMP1 and...